Gelişmiş Arama

Basit öğe kaydını göster

Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors

dc.contributor.authorErfan, Gamze
dc.contributor.authorPuig, Susana
dc.contributor.authorCarrera, Cristina
dc.contributor.authorArance, Ana
dc.contributor.authorGaba, Lydia
dc.contributor.authorVictoria, Ivan
dc.contributor.authorMalvehy, Josep
dc.date.accessioned2022-05-11T14:37:19Z
dc.date.available2022-05-11T14:37:19Z
dc.date.issued2017
dc.identifier.issn0001-5555
dc.identifier.issn1651-2057
dc.identifier.urihttps://doi.org/10.2340/00015555-2488
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8658
dc.description.abstract[No Abstract Available]en_US
dc.description.sponsorshipFondo de Investigaciones Sanitarias, SpainInstituto de Salud Carlos III [09/1393, 12/00840]; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain; Fondo Europeo de Desarrollo Regional (FEDER) from European Comission, Una manera de hacer Europa; Catalan Government, Spain [AGAUR 2009 SGR 1337, AGAUR 2014_SGR_603]; European Commission under the 6th Framework ProgrammeEuropean Commission [LSHC-CT-2006-018702]; National Cancer Institute (NCI) of the US National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA83115]en_US
dc.description.sponsorshipThe research at the Melanoma Unit in Barcelona is partially funded by Grants 09/1393 and 12/00840 from Fondo de Investigaciones Sanitarias, Spain; by the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain & Fondo Europeo de Desarrollo Regional (FEDER) from the European Comission, Una manera de hacer Europa; by the AGAUR 2009 SGR 1337 and AGAUR 2014_SGR_603 of the Catalan Government, Spain; by the European Commission under the 6th Framework Programme, Contract no : LSHC-CT-2006-018702 (GenoMEL) and by the National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115).en_US
dc.language.isoengen_US
dc.publisherActa Dermato-Venereologicaen_US
dc.identifier.doi10.2340/00015555-2488
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetastatic Melanomaen_US
dc.subjectVemurafeniben_US
dc.subjectMutationsen_US
dc.subjectDabrafeniben_US
dc.subjectSurvivalen_US
dc.titleDevelopment of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitorsen_US
dc.typeeditorialMaterialen_US
dc.relation.ispartofActa Dermato-Venereologicaen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0003-1608-8820
dc.authorid0000-0003-0000-5568
dc.authorid0000-0003-1337-9745
dc.authorid0000-0003-2896-1957
dc.authorid0000-0002-6998-914X
dc.authorid0000-0003-4156-1587
dc.identifier.volume97en_US
dc.identifier.issue2en_US
dc.identifier.startpage258en_US
dc.identifier.endpage260en_US
dc.institutionauthorErfan, Gamze
dc.relation.publicationcategoryDiğeren_US
dc.authorscopusid27867662800
dc.authorscopusid57213502354
dc.authorscopusid36870183300
dc.authorscopusid6603325754
dc.authorscopusid55308543300
dc.authorscopusid39561613500
dc.authorscopusid24775472700
dc.authorwosidCARRERA, CRISTINA/N-1887-2019
dc.authorwosidErfan, Gamze/W-8139-2018
dc.authorwosidPuig, Susana/AAB-2091-2020
dc.identifier.wosWOS:000393895500017en_US
dc.identifier.scopus2-s2.0-85012008964en_US
dc.identifier.pmid27353949en_US


Bu öğenin dosyaları:

Thumbnail
Ad:
8658.pdf
Boyut:
253.2Kb
Biçim:
PDF
Açıklama:
Tam Metin / Full Text
Göster/Aç

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster